Active	Status	Sponsor type	Region	Phase	Filter
4 Active 1 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
LOCHER, Chrystèle
ELDERLY, NCT03977194: Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy	Active, not recruiting	3	500	Europe	Carboplatin, Paclitaxel, Atezolizumab	Intergroupe Francophone de Cancerologie Thoracique	Non Small Cell Lung Cancer Metastatic	12/24	12/26
PERSEE, NCT04547504: PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 %	Recruiting	3	292	Europe	Pembrolizumab, Pembrolizumab and Chemotherapy drugs	University Hospital, Brest, Groupe Français de Pneumo-Cancérologie	Non-small-cell Lung Cancer	12/25	12/25
DIAL, NCT05255302 / 2021-006044-27: De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction	Recruiting	2/3	1360	Europe	Pembrolizumab before randomization, Chemotherapy, Pemetrexed, Pembrolizumab after randomization	Intergroupe Francophone de Cancerologie Thoracique, IFCT	Metastatic NSCLC	06/24	06/29
FIRST-NEC, NCT06393816: (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum	Not yet recruiting	2	80	Europe	Durvalumab with etoposide and Carboplatin/Cisplatin, MEDI4736	Centre Leon Berard, Groupe Français de Pneumo-Cancérologie	Large Cell Neuroendocrine Carcinoma of the Lung	09/28	09/29